EP Patent

EP2144887A1 — Dosages and methods for the treatment of cancer

Assigned to Myrexis Inc · Expires 2010-01-20 · 16y expired

What this patent protects

In general, the invention relates to a pharmaceutical dose having (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride as the active ingredient that upon administration to a subject provides a C<SUB>max</SUB> of about 1 ng/mL to about 250 ng/mL. Th…

USPTO Abstract

In general, the invention relates to a pharmaceutical dose having (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride as the active ingredient that upon administration to a subject provides a C<SUB>max</SUB> of about 1 ng/mL to about 250 ng/mL. The dose may be used in methods of treating cancer through the administration of (4-Methoxy-phenyl)-methyl-(2-methyl-quinazolin-4-yl)-amine hydrochloride. The composition of the invention is formulated with one or more pharmaceutically acceptable excipients, salts or carriers.

Drugs covered by this patent

Patent Metadata

Patent number
EP2144887A1
Jurisdiction
EP
Classification
—
Expires
2010-01-20
Drug substance claim
No
Drug product claim
No
Assignee
Myrexis Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.